Tinzaparin sodium for thrombosis treatment and prevention during pregnancy

Am J Obstet Gynecol. 2004 Feb;190(2):495-501. doi: 10.1016/s0002-9378(03)00953-0.


Objective: This study was undertaken to assess the pharmacodynamic profile, safety, and efficacy of tinzaparin during pregnancy.

Study design: Fifty-four pregnant women, 12 for treatment of thrombosis and 42 for thromboprophylaxis, received tinzaparin by once daily injection. Four-hour postdose anti-Xa results were analyzed by use of repeated measures statistical methods.

Results: One woman (3.4%) on the 175 anti-Xa U/kg dose and three women (20%) on the 50 anti-Xa U/kg dose required a dose increase during the initial dose titration phase to achieve target anti-Xa activity. No thrombotic events occurred.

Conclusion: The 175 anti-Xa U/kg dose is appropriate for treatment and for high-risk thromboprophylaxis throughout pregnancy. In pregnant women at moderate risk of thrombosis, a higher tinzaparin dose is required than in the nonpregnant state and 75 anti-Xa U/kg appears to be appropriate. The majority of women do not need a dose increase with advancing gestation.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / therapeutic use
  • Gestational Age
  • Heparin, Low-Molecular-Weight / administration & dosage*
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Complications, Cardiovascular / prevention & control
  • Pregnancy Outcome
  • Prospective Studies
  • Tinzaparin
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / prevention & control


  • Fibrinolytic Agents
  • Heparin, Low-Molecular-Weight
  • Tinzaparin